Transgenic amplification of glucocorticoid action in adipose tissue causes high blood pressure in mice.
about
Glucocorticoid regulation of the circadian clock modulates glucose homeostasisThe role of glucocorticoid action in the pathophysiology of the Metabolic SyndromePharmacophore Models and Pharmacophore-Based Virtual Screening: Concepts and Applications Exemplified on Hydroxysteroid DehydrogenasesEnzymatic intracrine regulation of white adipose tissueAdipose tissue and adrenal glands: novel pathophysiological mechanisms and clinical applicationsModulation of 11β-hydroxysteroid dehydrogenase as a strategy to reduce vascular inflammationMutations of key hydrophobic surface residues of 11β-hydroxysteroid dehydrogenase type 1 increase solubility and monodispersity in a bacterial expression systemOptimization of 1,2,4-Triazolopyridines as Inhibitors of Human 11β-Hydroxysteroid Dehydrogenase Type 1 (11β-HSD-1)Obesity-hypertension: an ongoing pandemic.11beta-hydroxysteroid dehydrogenase type 1 inhibitors for the treatment of type 2 diabetes.11beta-hydroxysteroid dehydrogenase type 1 expression is increased in the aged mouse hippocampus and parietal cortex and causes memory impairments.Tissue-specific increases in 11beta-hydroxysteroid dehydrogenase type 1 in normal weight postmenopausal women.Discovery of 2-Alkyl-1-arylsulfonylprolinamides as 11β-Hydroxysteroid Dehydrogenase Type 1 InhibitorsAdipocyte-specific glucocorticoid inactivation protects against diet-induced obesityGenome-wide analysis of glucocorticoid receptor binding regions in adipocytes reveal gene network involved in triglyceride homeostasis.Metabolic syndrome without obesity: Hepatic overexpression of 11beta-hydroxysteroid dehydrogenase type 1 in transgenic mice11β-HSD1 is the major regulator of the tissue-specific effects of circulating glucocorticoid excessDiscovery of Novel Insulin Sensitizers: Promising Approaches and Targets.Effect of 11 beta-hydroxysteroid dehydrogenase-1 inhibition on hepatic glucose metabolism in the conscious dog.11β-Hydroxysteroid dehydrogenase-1 is involved in bile acid homeostasis by modulating fatty acid transport protein-5 in the liver of mice.The renin angiotensin system and the metabolic syndromeCurrent therapies and emerging drugs in the pipeline for type 2 diabetes.The 11-beta-hydroxysteroid dehydrogenase type 1 inhibitor INCB13739 improves hyperglycemia in patients with type 2 diabetes inadequately controlled by metformin monotherapy.A novel 11β-hydroxysteroid dehydrogenase type1 inhibitor CNX-010-49 improves hyperglycemia, lipid profile and reduces body weight in diet induced obese C57B6/J mice with a potential to provide cardio protective benefits.Cardiac remodeling in obesity.11β-Hydroxysteroid dehydrogenase type 1: relevance of its modulation in the pathophysiology of obesity, the metabolic syndrome and type 2 diabetes mellitus.Regulation of adipocyte 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) by CCAAT/enhancer-binding protein (C/EBP) β isoforms, LIP and LAP.Increased whole-body and sustained liver cortisol regeneration by 11beta-hydroxysteroid dehydrogenase type 1 in obese men with type 2 diabetes provides a target for enzyme inhibitionFeed-forward inhibition of androgen receptor activity by glucocorticoid action in human adipocytes.Dexamethasone promotes hypertension by allele-specific regulation of the human angiotensinogen geneDiscovery of adamantyl heterocyclic ketones as potent 11β-hydroxysteroid dehydrogenase type 1 inhibitorsAdamantyl ethanone pyridyl derivatives: potent and selective inhibitors of human 11β-hydroxysteroid dehydrogenase type 111beta-hydroxysteroid dehydrogenase type 1 as a novel therapeutic target in metabolic and neurodegenerative disease.G6PT-H6PDH-11βHSD1 triad in the liver and its implication in the pathomechanism of the metabolic syndrome.Peripheral mechanisms contributing to the glucocorticoid hypersensitivity in proopiomelanocortin null mice treated with corticosterone.The role of cortisol in the pathogenesis of the metabolic syndromeTissue-specific dysregulation of 11beta-hydroxysteroid dehydrogenase type 1 and pathogenesis of the metabolic syndrome.The expression of 11β-hydroxysteroid dehydrogenase type 1 is increased in experimental periodontitis in ratsGenetic manipulation of 11beta-hydroxysteroid dehydrogenases in mice.Lack of significant metabolic abnormalities in mice with liver-specific disruption of 11β-hydroxysteroid dehydrogenase type 1.
P2860
Q24657351-5550D871-5959-4E26-AC7B-B34763C9BF20Q24803696-939844B4-02DC-4FCC-BDFF-C46A6E5DEFE2Q26772046-DD4CCA29-CC4A-4BA1-85EA-2AB134F11FBFQ26851926-3B4BCE04-5D4F-4EB1-9CAC-AD710D0EB744Q26860227-BB877C4E-C6A7-44D9-AC63-ABEA940B5B74Q26998660-1381263A-8D21-43D3-B02C-6ADDF95EF305Q27655825-8549D6A1-631F-43BE-B451-F54749D33E68Q27684779-86990088-4435-4637-ADD1-3B8F871795A1Q30359525-7336AFF2-E39F-4CA4-8528-489D40689EBDQ30392597-665E7F21-3FEB-4B1C-98A2-3299137B1331Q30494882-14A025D2-5AC4-4A9F-ADC9-0637A7CCC201Q33521207-BD0D35FD-8F28-4A65-B9D3-5BDA4D4A348BQ33630245-E94A7B36-C78F-44E3-A091-F9BCF92917BFQ33641373-E29F6824-D2C8-4F8C-85F2-75536E9AF73BQ33781016-4F7E7A32-D206-4413-A925-7CB05536FCA5Q33782682-37680C15-8E74-49F9-97E5-476D3221A6FDQ33789944-3969BFD6-27F1-4EAE-B5C6-2B3737C7E4DDQ33808884-18366418-7FDC-4121-AC3E-60177B670AA9Q33840328-FF9F3ECD-5435-4D7F-B577-CA5911C21BCCQ33906419-76808CD1-FB2E-4403-A09A-D275B409B5A7Q33915412-12B9983E-721E-49EA-AEC5-FB38EA2490A8Q33928941-05AB43E3-9E64-4EDD-8B28-553123B42B1FQ33932723-FE2C6E49-E432-41F1-8DC6-CCD44EA1D068Q34023395-4CF1600B-E2F7-4EAD-8C67-077CF1F25D50Q34043589-80BF68BE-B23D-464B-BC34-4043CA5F60A1Q34253331-6C49C661-5B39-438D-BE7D-1232765D92E4Q34291446-6DC97CA4-9970-4D1D-BB74-7FBC9F7D13BDQ34615362-255FCC09-9267-4899-A10E-62741B6137F5Q34657242-EA197515-FEF6-4722-9CEB-61A1D1676C0EQ35126691-E087C449-6A70-402D-8466-54AA0963274BQ35207855-D172672B-1830-48F3-BE49-22CC776AE6EBQ35231710-FFD488A9-1997-4E52-80C5-4AAFBC43D33AQ35593949-E36F2B77-5A4C-447B-BB9E-22EC511AF96EQ35937728-CB607880-364D-43DF-9BAB-2708FDDE219AQ36014459-F8945256-C8BA-423A-9F05-65029416AB6AQ36049207-F156FFC2-B8E8-4B10-9B6E-E30EB94C71C9Q36068444-BFE8F453-4AAD-492A-9B67-C2248DCD0335Q36156958-D2928782-E4CC-45DC-8DF8-A3779D07DAAAQ36232568-43BBC0B6-77BB-4642-BA6D-689DBA474812Q36331122-8A809224-098F-4FC6-9235-74EEEEEC2320
P2860
Transgenic amplification of glucocorticoid action in adipose tissue causes high blood pressure in mice.
description
2003 nî lūn-bûn
@nan
2003 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Transgenic amplification of gl ...... s high blood pressure in mice.
@ast
Transgenic amplification of gl ...... s high blood pressure in mice.
@en
type
label
Transgenic amplification of gl ...... s high blood pressure in mice.
@ast
Transgenic amplification of gl ...... s high blood pressure in mice.
@en
prefLabel
Transgenic amplification of gl ...... s high blood pressure in mice.
@ast
Transgenic amplification of gl ...... s high blood pressure in mice.
@en
P2093
P2860
P356
P1476
Transgenic amplification of gl ...... s high blood pressure in mice.
@en
P2093
Christopher J Kenyon
Hiroaki Masuzaki
Hiroshi Shinyama
Hiroshi Yamamoto
Janice M Paterson
Jeffrey S Flier
Joel K Elmquist
John J Mullins
Jonathan R Seckl
Matthew G F Sharp
P2860
P356
10.1172/JCI17845
P407
P577
2003-07-01T00:00:00Z